Phio Pharmaceuticals Corp.: completes first commercial-scale cGMP batch

What happened On Oct 13, 2026, Phio Pharmaceuticals Corp. issued a press release announcing the successful completion of its first commercial-scale cGMP Batch of PH-762 drug substance. The filing states this supports the planned initiation of the company's Phase 2b clinical trial in the first quarter of 2027.

Key details

• The company "announced the successful completion" of its first commercial-scale cGMP Batch of PH-762 drug substance on Oct 13, 2026.
• The filing links that completion to the planned initiation of the company's Phase 2b clinical trial in the first quarter of 2027.
• The company issued a press release to disclose the event.

Why it may matter Item 8.01 (other events) was reported; Item 8.01 covers events the company considers important enough to disclose outside the standard items of the form, such as press releases about operational developments. The filing does not show why the insider traded or why the company acted.